Eli Lilly on Thursday released results from TRIUMPH-1, its pivotal Phase 3 trial for the experimental obesity drug retatrutide, showing that participants on the highest dose lost an average of 70.3 ...
Eli Lilly said its next-generation drug cleared a crucial late-stage trial in patients with obesity, delivering significant weight loss across doses. The results bring Lilly one step closer to filing ...
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
iPercent body weight reduction with retatrutide 4 mg was a key secondary endpoint. iiThe extension period enrolled 532 participants with BMI ≥35 at baseline who had completed the main 80-week study ...
Retatrutide, Eli Lilly’s first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the TRIUMPH-1 phase 3 trial. Retatrutide is an investigational, ...
Retatrutide met primary and key secondary endpoints in a 2339-participant, randomized, double-blind, placebo-controlled phase 3 trial, demonstrating clinically meaningful weight reduction across 4, 9, ...
3D Systems (DDD Quick Quote DDD - Free Report) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.21 per share a ...
Share on Pinterest A new GLP-1 drug shows promise for improving metabolic health and treating obesity-related diseases like liver disease. camacho9999/Getty Images Boehringer Ingelheim, a ...
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss VDPHL01, a novel orally-administered extended-release ...
Veradermics announced Monday that its experimental oral hair loss pill, VDPHL01, met all primary and key secondary endpoints in a late-stage clinical trial. Veradermics stock (NYSE: MANE) was up 45% ...
April 14 (Reuters) - President Donald Trump's administration plans to launch next Monday the system it will use for issuing refunds to American importers for $166 billion the companies paid in tariffs ...
Every year across Australia, more than 100,000 people obtain a family violence protection order. For some victim-survivors, protection orders provide a much-needed safety net. They can help prevent ...
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Structure Therapeutics said Monday that its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results